Physician profile
Stephen Michael Bane
NPI 1528046349
$2,228.51
in general payments reported to CMS, 2019-2025
21 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $67.62 · 2021: $198 · 2022: $235 · 2023: $459 · 2024: $414 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $56.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.77 |
| Education | $56.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $938.61 | 2019-2025 | |
| Genzyme Corporation | $278.48 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $198.53 | 2022-2025 | Dupixent |
| Stryker Corporation | $148.35 | 2022-2024 | Xpress Ent Dilation System, Audion Et Dilation System |
| Glaxosmithkline, LLC. | $141.26 | 2021-2025 | Nucala |
| Acclarent, INC | $96.91 | 2021 | |
| Aerin Medical INC. | $57.39 | 2024-2025 | |
| Alk-Abello, INC | $48.46 | 2019-2025 | Alternaria Tenuis, Standardized Mite D. Farinae, Pre-Pen |
| Ars Pharmaceuticals Operations, INC. | $47.47 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $44.30 | 2019-2024 | |
| Intersect Ent, INC. | $29.61 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $27.68 | 2025 | Tezspire |
| Integra Lifesciences Corporation | $27.41 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Novo Nordisk INC | $22.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $19.91 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Medtronic, INC. | $19.46 | 2023 | Propel |
| Hikma Pharmaceuticals USA | $18.55 | 2023 | Ryaltris |
| Resmed Corp | $16.12 | 2019 | |
| Olympus America INC. | $15.67 | 2023 | |
| Arbor Pharmaceuticals, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.